Tag Archives: Momenta Pharmaceuticals

January, 2017

November, 2016

  • 30 November

    Momenta’s Humira Biosimilar Succeeds in Late-Stage Psoriasis Study

    CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate developed in collaboration with Baxalta, now part of Shire plc, in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint. The proportion …

August, 2016

  • 5 August

    Momenta Halts Late-Stage Pancreatic Cancer Trial After Interim Analysis

    CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib in combination with Abraxane® and gemcitabine in patients with advanced …

January, 2016

  • 8 January

    Mylan Partners with Momenta to Develop Six Biosimilar Products

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has entered into an exclusive global collaboration agreement with Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) to develop, manufacture and commercialize six of Momenta’s current biosimilar candidates, including Momenta’s biosimilar candidate, ORENCIA® (abatacept). Mylan …

December, 2015

April, 2015